Market Update – March 31, 2008
The first quarter witnessed excessive selling and growing fear. In this landscape, it is easy to overlook areas with upside potential. For many weeks, trend following tools, valuations measures and technical indicators have indicated buy points. Nonetheless, most investors have not subscribed to the idea that markets are “cheap”. For that reason, there is great tendency to neglect value due to lack of patience and mainstream worries. For example, performance chasing in commodity related areas produced speculative moves which are rather risky. Similarly, buying Financials because of steep declines has not been rewarding. In taking a step back, the long-term picture is appealing for Technology, Media, Telecom, cash rich and innovative based companies.
Specific Ideas:
Telecom:
In telecom, sector specific funds present a better strategy given that stock selection is tricky while the stocks trade uniformly. VZ (Verizon) and T (AT&T) are oversold and setting up for a recovery. Also, election speculation can play a major factor in the months ahead. Nonetheless, the sector is favorable. In fact so far in March, Telecommunication Services is the best performing sector (+3.12%) in the S&P 500.
Technology:
ORCL (Oracle): Despite last weeks sharp declines after earnings announcement. The stock is trading near long-term support of $19. As selling settles down, long-term investors can accumulate in the weeks ahead. ORCL is reaching oversold levels and offers favorable fundamentals versus its peers.
GLW (Corning): Early signs of recovery. Stock is attempting to breakout from current trading range ($23-24). Growth remains solid while demand for silicon products is higher than consensus expectations. (According to Matrix Group).
Consumer Staples:
WMT (Wal-Mart): Strength continues as the stock is up nearly 25% since January 14, 2008. In the near-time, declines in shares present buying opportunities. Positive fundamentals in the past 5-10 years and rewarding dividends should create higher investor demand.
Biotech:
GENZ(Genzyme): Fundamentals remain solid. Next resistance level is annual highs of $82.08 reached on January 17th. Plus, relative strength is positive and profitability appears slightly underestimated among analysts.